Trials / Completed
CompletedNCT04557774
Cognitive Function of Alcoholic Compensated Liver Cirrhosis
Cognitive Function of Alcoholic Liver Disease Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 110 (actual)
- Sponsor
- Chuncheon Sacred Heart Hospital · Academic / Other
- Sex
- All
- Age
- 22 Years – 69 Years
- Healthy volunteers
- Accepted
Summary
Differences in cognitive function between patients with viral and alcoholic compensated liver cirrhosis
Detailed description
Hepatic encephalopathy (HE) is one of the important complications of liver cirrhosis (LC). HE exhibits alterations in cognitive, psychomotor-intellectual, emotional, behavioral, or fine-motor functions. Approximately 22-74 % of patients with non-fulminant HE have MHE with a frequency proportional to the patient age and the severity of the liver disease. Patients with MHE exhibit disability in most functional behaviors such as social connection, alertness, emotional behavior, sleep, work, and leisure. Alcohol consumption itself has a toxic effect on the brain. It has been documented that there is a neuronal loss in the cerebral cortex, hypothalamus, hippocampus, septal region, and cerebellum of an alcoholic brain. The major causes of LC are hepatitis B/C viral infection and chronic alcohol consumption. The most widely accepted theory of HE pathogenesis is that toxic substances derived from the gut affect cerebral function after liver dysfunction or portosystemic shunting. This proposed pathogenetic mechanism could apply to viral compensated LC. However, it is difficult to explain the development of MHE in patients with alcoholic LC in this manner. Therefore, patients with alcoholic LC may have different cognitive dysfunction as compared to patients with viral LC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Cognitive function test | Laboratory and imaging test * Biochemical serum test: total bilirubin, alanine aminotransferase (ALT), haptoglobin, aspartate aminotransferase (AST), gamma glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), albumin, blood urea nitrogen, creatinine, α-fetoprotein (AFP), prothrombin time, blood glucose, triglycerides, and total cholesterol. * Baseline evaluations: family and alcohol history, X-ray, electrocardiography, blood tests for electrolyte, liver function, and viral markers Neuropsychological test -Attention, Language, Visuospatial, Memory, Frontal/executive |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2013-03-01
- Completion
- 2020-05-01
- First posted
- 2020-09-22
- Last updated
- 2020-09-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04557774. Inclusion in this directory is not an endorsement.